These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34220542)

  • 1. p21-Activated Kinase 1 Is Permissive for the Skeletal Muscle Hypertrophy Induced by Myostatin Inhibition.
    Barbé C; Loumaye A; Lause P; Ritvos O; Thissen JP
    Front Physiol; 2021; 12():677746. PubMed ID: 34220542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Proteomic and Transcriptomic Analysis of Follistatin-Induced Skeletal Muscle Hypertrophy.
    Barbé C; Bray F; Gueugneau M; Devassine S; Lause P; Tokarski C; Rolando C; Thissen JP
    J Proteome Res; 2017 Oct; 16(10):3477-3490. PubMed ID: 28810121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of IGF-I in follistatin-induced skeletal muscle hypertrophy.
    Barbé C; Kalista S; Loumaye A; Ritvos O; Lause P; Ferracin B; Thissen JP
    Am J Physiol Endocrinol Metab; 2015 Sep; 309(6):E557-67. PubMed ID: 26219865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy.
    Glass DJ
    Curr Top Microbiol Immunol; 2010; 346():267-78. PubMed ID: 20593312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin.
    Gilson H; Schakman O; Kalista S; Lause P; Tsuchida K; Thissen JP
    Am J Physiol Endocrinol Metab; 2009 Jul; 297(1):E157-64. PubMed ID: 19435857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The type 1 insulin-like growth factor receptor (IGF-IR) pathway is mandatory for the follistatin-induced skeletal muscle hypertrophy.
    Kalista S; Schakman O; Gilson H; Lause P; Demeulder B; Bertrand L; Pende M; Thissen JP
    Endocrinology; 2012 Jan; 153(1):241-53. PubMed ID: 22087027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local myostatin inhibition improves skeletal muscle glucose uptake in insulin-resistant high-fat diet-fed mice.
    Eilers W; Chambers D; Cleasby M; Foster K
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E163-E174. PubMed ID: 32459523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.
    Nakatani M; Takehara Y; Sugino H; Matsumoto M; Hashimoto O; Hasegawa Y; Murakami T; Uezumi A; Takeda S; Noji S; Sunada Y; Tsuchida K
    FASEB J; 2008 Feb; 22(2):477-87. PubMed ID: 17893249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy.
    Lee YS; Lehar A; Sebald S; Liu M; Swaggart KA; Talbot CC; Pytel P; Barton ER; McNally EM; Lee SJ
    Hum Mol Genet; 2015 Oct; 24(20):5711-9. PubMed ID: 26206886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF and myostatin pathways are respectively induced during the earlier and the later stages of skeletal muscle hypertrophy induced by clenbuterol, a β₂-adrenergic agonist.
    Abo T; Iida RH; Kaneko S; Suga T; Yamada H; Hamada Y; Yamane A
    Cell Biochem Funct; 2012 Dec; 30(8):671-6. PubMed ID: 22696074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant negative myostatin produces hypertrophy without hyperplasia in muscle.
    Zhu X; Hadhazy M; Wehling M; Tidball JG; McNally EM
    FEBS Lett; 2000 May; 474(1):71-5. PubMed ID: 10828454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of myostatin and bone morphogenetic proteins in muscular disorders.
    Tsuchida K
    Expert Opin Biol Ther; 2006 Feb; 6(2):147-54. PubMed ID: 16436040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease.
    Chen JL; Walton KL; Hagg A; Colgan TD; Johnson K; Qian H; Gregorevic P; Harrison CA
    Proc Natl Acad Sci U S A; 2017 Jun; 114(26):E5266-E5275. PubMed ID: 28607086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle.
    Han X; Møller LLV; De Groote E; Bojsen-Møller KN; Davey J; Henríquez-Olguin C; Li Z; Knudsen JR; Jensen TE; Madsbad S; Gregorevic P; Richter EA; Sylow L
    J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1241-1257. PubMed ID: 31402604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myostatin signaling regulates Akt activity via the regulation of miR-486 expression.
    Hitachi K; Nakatani M; Tsuchida K
    Int J Biochem Cell Biol; 2014 Feb; 47():93-103. PubMed ID: 24342526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia.
    Sun DF; Chen Y; Rabkin R
    Kidney Int; 2006 Aug; 70(3):453-9. PubMed ID: 16871256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis.
    Nakatani M; Kokubo M; Ohsawa Y; Sunada Y; Tsuchida K
    Am J Physiol Endocrinol Metab; 2011 Mar; 300(3):E543-53. PubMed ID: 21205933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
    Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
    Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size.
    Trendelenburg AU; Meyer A; Rohner D; Boyle J; Hatakeyama S; Glass DJ
    Am J Physiol Cell Physiol; 2009 Jun; 296(6):C1258-70. PubMed ID: 19357233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.